AptarGroup, Inc.
ATR Healthcare Medical Instruments & Supplies
AptarGroup, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.8 billion, up 5.42% from fiscal 2024. In the quarter to June 2026, revenue grew 6.26%, EPS fell 18.3%, free cash flow fell 23.1% and total debt rose 66.4%, each against the same quarter a year earlier. Dividend growth for ten consecutive years, revenue growth for ten.
Follow ATR
AptarGroup, Inc. (ATR) EV/Sales
As of 16 October 2026, AptarGroup, Inc. (ATR) trades at a EV/Sales of 2.3×. Over the past ten years it has ranged from 1.6× (January 2015) to 3.7× (May 2021); the current reading is higher than 22% of that period. That is below the Medical Instruments & Supplies industry median of 2.9× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.4× | (23.15%) |
| FY2024 | 3.1× | 22.77% |
| FY2023 | 2.6× | 2.84% |
| FY2022 | 2.5× | (10.73%) |
| FY2021 | 2.8× | (15.54%) |
| FY2020 | 3.3× | 13.92% |
| FY2019 | 2.9× | 17.43% |
| FY2018 | 2.5× | 1.69% |
| FY2017 | 2.4× | 15.13% |
| FY2016 | 2.1× | 0.58% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 2.3× | (2.29%) |
| Mar 2026 | 2.4× | (1.22%) |
| Dec 2025 | 2.4× | (9.30%) |
| Sep 2025 | 2.7× | (12.71%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| BLCO Bausch + Lomb Corporation compare | 2.0× |
| AVTR Avantor, Inc. compare | 2.2× |
| ALGN Align Technology, Inc. compare | 2.3× |
| ATR AptarGroup, Inc. | 2.3× |
| COO The Cooper Companies, Inc. compare | 3.2× |
| MMSI Merit Medical Systems, Inc. compare | 3.6× |
| TFX Teleflex Incorporated compare | 3.6× |
| STVN Stevanato Group S.p.A. compare | 3.9× |
| RGEN Repligen Corporation compare | 12.3× |
| Medical Instruments & Supplies industry median | 2.9× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)